Thomas D Coates

List of Publications by Year
in descending order

276 papers	10,689 citations	31976 53 h-index	37204 96 g-index
281 all docs	281 docs citations	281 times ranked	7731 citing authors

#	Article	IF	Citations
1	Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease. American Journal of Hematology, 2021, 96, 60-68.	4.1	2
2	Kidney iron deposition by R2* is associated with haemolysis and urinary iron. British Journal of Haematology, 2021, 193, 633-636.	2.5	3
3	Loss of alphaâ€globin genes in human subjects is associated with improved nitric oxideâ€mediated vascular perfusion. American Journal of Hematology, 2021, 96, 277-281.	4.1	12
4	Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups â€•revisiting this controversial concept after 16â€‰years of additional evidence. American Journal of Hematology, 2021, 96, 31-39.	4.1	10
5	Tractâ€specific analysis and neurocognitive functioning in sickle cell patients without history of overt stroke. Brain and Behavior, 2021, 11, e01978.	2.2	7
6	Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia. American Journal of Hematology, 2021, 96, E165-E168.	4.1	5
7	Calibration of T₂ oximetry MRI for subjects with sickle cell disease. Magnetic Resonance in Medicine, 2021, 86, 1019-1028.	3.0	17
8	Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias. American Journal of Hematology, 2021, 96, 901-913.	4.1	20
9	Identifying Elevated Risk for Future Pain Crises in Sickle-Cell Disease Using Photoplethysmogram Patterns Measured During Sleep: A Machine Learning Approach. Frontiers in Digital Health, 2021, 3, .	2.8	4
10	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	2.2	13
11	Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. British Journal of Haematology, 2021, 195, e160-e164.	2.5	2
12	Individual red blood cell nitric oxide production in sickle cell anemia: Nitric oxide production is increased and sickle shaped cells have unique morphologic change compared to discoid cells. Free Radical Biology and Medicine, 2021, 171, 143-155.	2.9	3
13	Effects of B 1 + Heterogeneity on Spin Echoâ€Based Liver Iron Estimates. Journal of Magnetic Resonance Imaging, 2021, , .	3.4	2
14	Vasoconstriction Response to Mental Stress in Sickle Cell Disease: The Role of the Cardiac and Vascular Baroreflexes. Frontiers in Physiology, 2021, 12, 698209.	2.8	3
15	A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent Î²-Thalassemia (TDT). Blood, 2021, 138, 4161-4161.	1.4	1
16	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	1.4	4
17	Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls. Haematologica, 2020, 105, 83-90.	3.5	40
18	Autonomically-mediated decrease in microvascular blood flow due to mental stress and pain in sickle cell disease: A target for neuromodulatory interventions. Complementary Therapies in Medicine, 2020, 49, 102334.	2.7	4

#	Article	IF	Citations
19	Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine, 2020, 30, 226-230.	1.1	5
20	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	27.0	177
21	Progressive vasoconstriction with sequential thermal stimulation indicates vascular dysautonomia in sickle cell disease. Blood, 2020, 136, 1191-1200.	1.4	14
22	Transient Hypoxia Model Revealed Cerebrovascular Impairment in Anemia Using <scp>BOLD MRI</scp> and <scp>Nearâ€Infrared</scp> Spectroscopy. Journal of Magnetic Resonance Imaging, 2020, 52, 1400-1412.	3.4	6
23	Aura and mental stress are associated with reports of pain in sickle cell diseaseâ€a pilot study using a mobile application. American Journal of Hematology, 2020, 95, E101-E103.	4.1	2
24	Fixing the MRI R2â€iron calibration in liver. American Journal of Hematology, 2020, 95, E120-E122.	4.1	3
25	Loss of Alpha Globin Genes in Human Subjects Is Associated with Improved Nitric Oxide-Mediated Vascular Perfusion. Blood, 2020, 136, 6-7.	1.4	1
26	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	1.4	8
27	Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents. Free Radical Biology and Medicine, 2019, 141, 408-415.	2.9	14
28	Anemia predicts lower white matter volume and cognitive performance in sickle and nonâ€sickle cell anemia syndrome. American Journal of Hematology, 2019, 94, 1055-1065.	4.1	28
29	Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger?. Journal of Clinical Medicine, 2019, 8, 1690.	2.4	23
30	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	3.2	33
31	Shared Care for Adults with Sickle Cell Disease: An Analysis of Care from Eight Health Systems. Journal of Clinical Medicine, 2019, 8, 1154.	2.4	6
32	White matter has impaired resting oxygen delivery in sickle cell patients. American Journal of Hematology, 2019, 94, 467-474.	4.1	31
33	Sickle Cell Disease Subjects Have a Distinct Abnormal Autonomic Phenotype Characterized by Peripheral Vasoconstriction With Blunted Cardiac Response to Head-Up Tilt. Frontiers in Physiology, 2019, 10, 381.	2.8	18
34	Introduction to a review series on human neutrophils. Blood, 2019, 133, 2111-2112.	1.4	5
35	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	3.5	43
36	Sickle cell microvascular paradoxâ€"oxygen supplyâ€demand mismatch. American Journal of Hematology, 2019, 94, 678-688.	4.1	14

#	Article	IF	Citations
37	Iron overload in transfusion-dependent patients. Hematology American Society of Hematology Education Program, 2019, 2019, 337-344.	2.5	25
38	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	5.2	87
39	Introduction to a review series on iron metabolism and its disorders. Blood, 2019, 133, 1-2.	1.4	5
40	Exploring Anemia's Impact on Brain Microstructure, Volume, Functional Connectivity, Iron and Cognitive Performance. Blood, 2019, 134, 3553-3553.	1.4	2
41	Kidney Iron Deposition By R2* Is Associated with Hemolysis and Urinary Iron. Blood, 2019, 134, 3537-3537.	1.4	0
42	High Levels of Peripheral Vasoconstriction Detected By Polysomnography Predict More Acute Severe Pain Episodes in Children with Sickle Cell Anemia. Blood, 2019, 134, 894-894.	1.4	0
43	Autonomic nervous system involvement in sickle cell disease. Clinical Hemorheology and Microcirculation, 2018, 68, 251-262.	1.7	25
44	You don't always get what you want: Does hypoxia cause sickle cell crisis?. American Journal of Hematology, 2018, 93, 475-477.	4.1	4
45	Ultraâ€short echo time images quantify high liver iron. Magnetic Resonance in Medicine, 2018, 79, 1579-1585.	3.0	38
46	Pseudo continuous arterial spin labeling quantification in anemic subjects with hyperemic cerebral blood flow. Magnetic Resonance Imaging, 2018, 47, 137-146.	1.8	29
47	Diminished cerebral oxygen extraction and metabolic rate in sickle cell disease using T2 relaxation under spin tagging MRI. Magnetic Resonance in Medicine, 2018, 80, 294-303.	3.0	49
48	Introduction to a How I Treat series on sickle cell disease and thalassemia. Blood, 2018, 132, 1729-1730.	1.4	0
49	Effectiveness of Clinical Decision Support Based Intervention in the Improvement of Care for Adult Sickle Cell Disease Patients in Primary Care. Journal of the American Board of Family Medicine, 2018, 31, 812-816.	1.5	10
50	A novel cross-correlation methodology for assessing biophysical responses associated with pain. Journal of Pain Research, 2018, Volume 11, 2207-2219.	2.0	7
51	Increased brain iron deposition in patients with sickle cell disease: an MRI quantitative susceptibility mapping study. Blood, 2018, 132, 1618-1621.	1.4	19
52	Orchestral fully convolutional networks for small lesion segmentation in brain MRI. , 2018, 2018, 889-892.		11
53	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	1.4	11
54	Sickle Cell Subjects Have a Stronger and Faster Neurally Mediated Vasoconstriction Response to Cold Pain That Correlates with Anxiety Scores. Blood, 2018, 132, 854-854.	1.4	2

#	Article	IF	Citations
55	Middle Cerebral Artery Velocities Are Inversely Related to Hemoglobin Levels and Acutely Drop in Response to RBC Transfusion: Implications for Stroke Screening in SCD. Blood, 2018, 132, 2374-2374.	1.4	0
56	Hemolysis and Tricuspid Regurgitation Jet Velocity Predict Mortality in Patients with Sickle Cell Disease. Blood, 2018, 132, 1086-1086.	1.4	0
57	Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later. American Journal of Hematology, 2017, 92, 411-413.	4.1	27
58	Emergency department utilization by Californians with sickle cell disease, 2005â€“2014. Pediatric Blood and Cancer, 2017, 64, e26390.	1.5	40
59	Hemoglobin and mean platelet volume predicts diffuse T1-MRI white matter volume decrease in sickle cell disease patients. NeuroImage: Clinical, 2017, 15, 239-246.	2.7	29
60	The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vasoâ€•occlusive crises. American Journal of Hematology, 2017, 92, 569-582.	4.1	33
61	How we manage iron overload in sickle cell patients. British Journal of Haematology, 2017, 177, 703-716.	2.5	71
62	Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain. American Journal of Hematology, 2017, 92, 1137-1145.	4.1	30
63	Graph Lasso-Based Test for Evaluating Functional Brain Connectivity in Sickle Cell Disease. Brain Connectivity, 2017, 7, 443-453.	1.7	10
64	Empirical model of human blood transverse relaxation at 3â€‰T improves MRI T₂oximetry. Magnetic Resonance in Medicine, 2017, 77, 2364-2371.	3.0	34
65	The effect of hypnosis on pain and peripheral blood flow in sickle-cell disease: a pilot study. Journal of Pain Research, 2017, Volume 10, 1635-1644.	2.0	24
66	Biophysical markers of the peripheral vasoconstriction response to pain in sickle cell disease. PLoS ONE, 2017, 12, e0178353.	2.5	29
67	Contrasting resting-state fMRI abnormalities from sickle and non-sickle anemia. PLoS ONE, 2017, 12, e0184860.	2.5	22
68	Determinants of resting cerebral blood flow in sickle cell disease. American Journal of Hematology, 2016, 91, 912-917.	4.1	76
69	Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?. Annals of the New York Academy of Sciences, 2016, 1368, 95-106.	3.8	30
70	Predictors of cerebral blood flow in patients with and without anemia. Journal of Applied Physiology, 2016, 120, 976-981.	2.5	42
71	Unchanneling cardiac iron in humans. Blood, 2016, 128, 1538-1540.	1.4	1
72	Changes in Brain Oxygenation in Response to Inhaled 100% Oxygen Are Different in Sickle Cell Disease Patients. Blood, 2016, 128, 3667-3667.	1.4	0

#	Article	IF	Citations
73	Hemoglobin Level and Platelet Size Predicts Grey and White Matter Volume Loss Measured By Tensor Based Morphology in Sickle Cell Disease. Blood, 2016, 128, 2481-2481.	1.4	0
74	Shear-Mediated Erythrocyte Nitric Oxide Production Is Differentially Regulated in Patients with Sickle Cell Disease. Blood, 2016, 128, 1301-1301.	1.4	0
75	Regional Susceptibility to Chronic Anemia in WM Microstructure Using Diffusion Tensor Imaging. Blood, 2016, 128, 3640-3640.	1.4	1
76	Chronic Transfusion Therapy in Sickle Cell Disease - Effect on Macrovascular Function, Microvascular Function, and Tissue Oxygenation Decreases the Potential for Ischemia. Blood, 2016, 128, 3671-3671.	1.4	0
77	Peripheral Blood Flow Responses to Pain Following a Hypnosis Intervention in Sickle Cell Disease. Blood, 2016, 128, 4853-4853.	1.4	0
78	Autonomic and Vascular Dysregulation Enhance Pain-Induced Peripheral Vasoconstriction in Sickle Cell Disease. Blood, 2016, 128, 126-126.	1.4	0
79	Regional Perfusion in Sickle Cell Subjects and Normal Controls Is a Physiological Biomarker of Mental Stress and Fear of Pain. Blood, 2016, 128, 2492-2492.	1.4	0
80	Hemoglobin S Exhibits Distinct MRI Oximetry Calibration in Vitro. Blood, 2016, 128, 4842-4842.	1.4	0
81	Autonomic responses to cold face stimulation in sickle cell disease: a time-varying model analysis. Physiological Reports, 2015, 3, e12463.	1.7	14
82	Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood, 2015, 126, 703-710.	1.4	62
83	Iron toxicity and its possible association with treatment of Cancer: Lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free Radical Biology and Medicine, 2015, 79, 343-351.	2.9	43
84	Pulmonary hypertension in well-transfused thalassemia major patients. Blood Cells, Molecules, and Diseases, 2015, 54, 189-194.	1.4	29
85	Iron and oxidative stress in cardiomyopathy in thalassemia. Free Radical Biology and Medicine, 2015, 88, 3-9.	2.9	81
86	A Significant Proportion of Thalassemia Major Patients Have Adrenal Insufficiency Detectable on Provocative Testing. Journal of Pediatric Hematology/Oncology, 2015, 37, 54-59.	0.6	27
87	Early Cardiac Iron Overload in a Child on Treatment of Acute Lymphoblastic Leukemia. Pediatrics, 2015, 136, e697-e700.	2.1	4
88	Cerebral Tissue Transit Time in Patients with Sickle Cell Anemia. Blood, 2015, 126, 280-280.	1.4	1
89	Infusion of Pegylated Bovine Carboxyhemoglobin (PEG-COHb) Is Associated with Rapid Reversal of Progressive Acute Chest Syndrome in a Jehovah's Witness Patient with Hemoglobin SC Sickle Cell Disease. Blood, 2015, 126, 4541-4541.	1.4	2
90	Thermal Pain and Pain Anticipation Induce a Decrease in Microvascular Perfusion in Sickle Cell and Normal Subjects. Blood, 2015, 126, 67-67.	1.4	2

#	Article	IF	Citations
91	Analysis of Hemodynamic Changes and Bold Signals of Sickle Cell Disease Patients during Desaturation. Blood, 2015, 126, 3384-3384.	1.4	0
92	Prediabetes, elevated iron and all-cause mortality: a cohort study. BMJ Open, 2014, 4, e006491.	1.9	13
93	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	1.6	97
94	Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatric Blood and Cancer, 2014, 61, 2271-2276.	1.5	39
95	Cardiac iron overload in sickleâ€cell disease. American Journal of Hematology, 2014, 89, 678-683.	4.1	67
96	Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. British Journal of Haematology, 2014, 166, 797-800.	2.5	7
97	The impact of chelation therapy on survival in transfusional iron overload: a metaâ€analysis of myelodysplastic syndrome. British Journal of Haematology, 2014, 167, 720-723.	2.5	49
98	Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. American Journal of Hematology, 2014, 89, 391-394.	4.1	73
99	Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radical Biology and Medicine, 2014, 72, 23-40.	2.9	130
100	Bad liver and a broken heart. Blood, 2014, 123, 1434-1436.	1.4	7
101	Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatric Blood and Cancer, 2014, 61, 869-874.	1.5	31
102	Elevated Cerebral Metabolic Oxygen Consumption in Sickle Cell Disease. Blood, 2014, 124, 2706-2706.	1.4	6
103	Elevated Cerebral Blood Oxygen Extraction in Non-Transfused Sickle Cell Disease Patients. Blood, 2014, 124, 1387-1387.	1.4	1
104	Cerebral Blood Flow and Metabolic Correlates of Near Infrared Spectroscopy in Patients with Sickle Cell Disease. Blood, 2014, 124, 1386-1386.	1.4	0
105	Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. Blood, 2014, 124, 4855-4855.	1.4	1
106	Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. American Journal of Hematology, 2013, 88, E283-5.	4.1	82
107	Lowâ€shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy. Transfusion, 2013, 53, 297-305.	1.6	28
108	Autonomic nervous system dysfunction: Implication in sickle cell disease. Comptes Rendus - Biologies, 2013, 336, 142-147.	0.2	27

#	Article	IF	Citations
109	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	2.5	7
110	Systematic Review of Transition From Adolescent to Adult Care in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2013, 35, 165-169.	0.6	65
111	Î²-globin gene transfer to human bone marrow for sickle cell disease. Journal of Clinical Investigation, 2013, 123, 3317-3330.	8.2	92
112	Pain in thalassaemia: the effects of age on pain frequency and severity. British Journal of Haematology, 2013, 160, 680-687.	2.5	29
113	Patients with sickle cell anemia on simple chronic transfusion protocol show sex differences for hemodynamic and hematologic responses to transfusion. Transfusion, 2013, 53, 1059-1068.	1.6	13
114	Exercise performance in thalassemia major: Correlation with cardiac iron burden. American Journal of Hematology, 2013, 88, 193-197.	4.1	18
115	Comparison of biventricular dimensions and function between pediatric sickleâ€cell disease and thalassemia major patients without cardiac iron. American Journal of Hematology, 2013, 88, 213-218.	4.1	20
116	Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Research and Human Retroviruses, 2013, 29, 1006-1009.	1.1	5
117	Cardiac Iron Overload In Sickle-Cell Disease. Blood, 2013, 122, 1013-1013.	1.4	1
118	Glucose Phosphate Isomerase Deficiency In 2 Patients With Novel Mutations Presenting As Severe Neurologic Abnormalities and Transfusion Dependent Hemolytic Anemia. Blood, 2013, 122, 947-947.	1.4	3
119	Cerebral Blood Flow and Oxygen Delivery In Response To Hyperoxia In Sickle Cell Anemia. Blood, 2013, 122, 2210-2210.	1.4	0
120	Change In Flow Mediated Dilation After Transfusion Is Dependent On BMI and Blood Age. Blood, 2013, 122, 3653-3653.	1.4	0
121	Pituitary Iron and Volume Imaging in Healthy Controls. American Journal of Neuroradiology, 2012, 33, 259-265.	2.4	17
122	Treating thalassemia major-related iron overload: the role of deferiprone. Journal of Blood Medicine, 2012, 3, 119.	1.7	42
123	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
124	Sickle cell disease in California: Sociodemographic predictors of emergency department utilization. Pediatric Blood and Cancer, 2012, 58, 66-73.	1.5	26
125	Electrocardiographic consequences of cardiac iron overload in thalassemia major. American Journal of Hematology, 2012, 87, 139-144.	4.1	46
126	Pancreatic iron and glucose dysregulation in thalassemia major. American Journal of Hematology, 2012, 87, 155-160.	4.1	118

#	Article	IF	Citations
127	Pituitary iron and volume predict hypogonadism in transfusional iron overload. American Journal of Hematology, 2012, 87, 167-171.	4.1	114
128	Delayed Recovery of Venous Oxygen Saturation and Lactate in SCT Subjects Following Exercise and Their Association with Red Cell Oxidative Stress. Blood, 2012, 120, 3244-3244.	1.4	0
129	Changes in Regional Oxygenation At the Site of Sickle Cell Vaso-Occlusive Pain. Blood, 2012, 120, 4773-4773.	1.4	0
130	Evaluation of Autonomic Function in Patients with Sickle Cell Disease in Relation to Nighttime Hypoxemia. Blood, 2012, 120, 4764-4764.	1.4	0
131	Changes in Pituitary Iron, Volume, and Function Over Two Years in Pediatric Patients Treated with Deferasirox. Blood, 2012, 120, 3206-3206.	1.4	13
132	Autonomic Response to Hypoxia and Isometric Exercise in Sickle Cell Trait Subjects. Blood, 2012, 120, 3241-3241.	1.4	0
133	Abnormal Red Cell Deformability and Aggregation in Sickle Cell Trait. Blood, 2012, 120, 1001-1001.	1.4	1
134	Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Review of Hematology, 2011, 4, 17-26.	2.2	31
135	So what if blood is thicker than water?. Blood, 2011, 117, 745-746.	1.4	11
136	Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica, 2011, 96, 1055-1058.	3.5	38
137	Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major. British Journal of Haematology, 2011, 152, 229-233.	2.5	27
138	Quantitative computed tomography assessment of transfusional iron overload. British Journal of Haematology, 2011, 153, 780-785.	2.5	21
139	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
140	Pulmonary function in thalassaemia major and its correlation with body iron stores. British Journal of Haematology, 2011, 155, 102-105.	2.5	13
141	Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. European Journal of Haematology, 2011, 86, 176-177.	2.2	8
142	Sickleâ€cell disease in California: A populationâ€based description of emergency department utilization. Pediatric Blood and Cancer, 2011, 56, 413-419.	1.5	34
143	Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatric Blood and Cancer, 2011, 56, 460-462.	1.5	46
144	Is it time to SWiTCH to composite primary endpoints?. Pediatric Blood and Cancer, 2011, 57, 906-907.	1.5	0

#	Article	IF	Citations
145	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	4.1	63
146	Peripheral Vasoconstriction and Abnormal Parasympathetic Response to Sighs and Transient Hypoxia in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 474-481.	5.6	55
147	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1
148	Preclinical Studies for Sickle Cell Disease Gene Therapy Using Bone Marrow CD34+ Cells Modified with a Î²AS3-Globin Lentiviral Vector. Blood, 2011, 118, 3119-3119.	1.4	13
149	Cardiac Iron Overload Causes Clinically Evident Heart Failure and Arrhythmia in Sickle Cell Anemia Patients: Evidence From Three Cases. Blood, 2011, 118, 4846-4846.	1.4	0
150	Liver and Cardiac Iron Measurements in Very Young Chronically Transfused Patients Show Dangerous Levels of Iron Loading. Blood, 2011, 118, 1086-1086.	1.4	0
151	What Predicts Adrenal Insufficiency in Patients with Thalassemia Major?. Blood, 2011, 118, 5299-5299.	1.4	0
152	In Patients with Sickle Cell Disease on Chronic Transfusion Therapy, Viscosity and Aggregation Are Increased After a Single Transfusion, Negatively Affecting Low Shear Rate Blood Flow. Blood, 2011, 118, 1259-1259.	1.4	0
153	Pituitary Iron and Volume Predicts Hypogonadal Hypogonadism in Transfusional Iron Overload. Blood, 2011, 118, 1094-1094.	1.4	0
154	Acute Cardiovascular and Hematologic Changes After a Single Transfusion Demonstrate Sex Differences in Chronically Transfused Sickle Cell Anemia Patients. Blood, 2011, 118, 2138-2138.	1.4	6
155	Trends in Ferritin Can Be Dramatically Different From Trends in Total Body Iron and Could Lead to Erroneous Decisions in Iron Chelation Management and Discourage Adherence in Chronically Transfused Patients,. Blood, 2011, 118, 3203-3203.	1.4	1
156	The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood, 2010, 116, 537-543.	1.4	127
157	Combining two orally active iron chelators for thalassemia. Annals of Hematology, 2010, 89, 1177-1178.	1.8	24
158	Pain as an emergent issue in thalassemia. American Journal of Hematology, 2010, 85, 367-370.	4.1	28
159	Followâ€up report on the 2â€year cardiac data from a deferasirox monotherapy trial. American Journal of Hematology, 2010, 85, 818-819.	4.1	13
160	Quantitative analysis and modelling of hepatic iron stores using stereology and spatial statistics. Journal of Microscopy, 2010, 238, 265-274.	1.8	16
161	Predicting pituitary iron and endocrine dysfunction. Annals of the New York Academy of Sciences, 2010, 1202, 123-128.	3.8	46
162	Sigh Induces A Decrease In Blood Flow And Increase In Spectral Density Of Blood Flow Oscillations In Sickle Cell Disease. , 2010, , .		0

#	Article	IF	Citations
163	DESIGN OF THE SILENT CEREBRAL INFARCT TRANSFUSION (SIT) TRIAL. Pediatric Hematology and Oncology, 2010, 27, 69-89.	0.8	108
164	Serologic Assessment for Inflammatory Bowel Disease in Patients with Chronic Granulomatous Disease. Pediatric, Allergy, Immunology, and Pulmonology, 2010, 23, 261-263.	0.8	2
165	Time-varying analysis of autonomic control in response to spontaneous sighs in sickle cell anemia. , 2010, 2010, 1626-9.		4
166	Sickle cell disease: Selected aspects of pathophysiology. Clinical Hemorheology and Microcirculation, 2010, 44, 155-166.	1.7	45
167	Combination of Two Orally Active Iron Chelating Agents: Efficacy and Safety In a Clinical Setting. Blood, 2010, 116, 2064-2064.	1.4	1
168	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
169	California Emergency Department Utilization in Patients with Sickle Cell Disease: Sociodemographic Predictors.. Blood, 2010, 116, 3820-3820.	1.4	0
170	Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. Blood, 2010, 116, 254-254.	1.4	1
171	Blood Flow Response to Cold Face Stimulation Is Blunted In Patients with Sickle Cell Disease. Blood, 2010, 116, 2655-2655.	1.4	0
172	Pulmonary Hypertension Is Uncommon In Well-Transfused Thalassemia Major Patients. Blood, 2010, 116, 4273-4273.	1.4	0
173	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	1.4	0
174	Pulmonary hypertension does not affect the autonomic nervous system dysfunction of sickle cell disease. American Journal of Hematology, 2009, 84, 311-312.	4.1	21
175	The cost of health care for children and adults with sickle cell disease. American Journal of Hematology, 2009, 84, 323-327.	4.1	368
176	Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. American Journal of Hematology, 2009, 84, 344-348.	4.1	86
177	Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. American Journal of Hematology, 2009, 84, 480-483.	4.1	25
178	Hemoglobin Hâ€constant spring in North America: An alpha thalassemia with frequent complications. American Journal of Hematology, 2009, 84, 759-761.	4.1	24
179	Spleen R2 and R2* in ironâ€overloaded patients with sickle cell disease and thalassemia major. Journal of Magnetic Resonance Imaging, 2009, 29, 357-364.	3.4	57
180	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638.	1.4	98

#	Article	IF	Citations
181	Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood, 2009, 114, 4021-4026.	1.4	137
182	Pituitary Iron and Volume in Transfusional Iron Overload.. Blood, 2009, 114, 2017-2017.	1.4	1
183	Health Care Disparities in Sickle Cell Disease : A Population-Based Study of Los Angeles County.. Blood, 2009, 114, 2480-2480.	1.4	1
184	Elevated Systolic Blood Pressure and Low Fetal Hemoglobin Are Risk Factors for Silent Cerebral Infarcts in Children with Sickle Cell Anemia.. Blood, 2009, 114, 262-262.	1.4	5
185	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
186	Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (ExjadeÂ®) Monotherapy in Chronically Transfused Î²-Thalassemia (Î²-Thal) Patients: 18- and 24-Month Data.. Blood, 2009, 114, 4069-4069.	1.4	1
187	Low Ascorbate Levels in Transfused Patients Are Associated with Correlates of Vascular Damage in Sickle Cell Disease.. Blood, 2009, 114, 2570-2570.	1.4	1
188	Acute Hemodynamic and Vascular Effects of Transfusion in Chronically Transfused Patients with Sickle Cell Anemia.. Blood, 2009, 114, 1516-1516.	1.4	0
189	Pituitary Iron and Volume in Transfusional Iron Overload: Normative Data.. Blood, 2009, 114, 4073-4073.	1.4	0
190	Decrease in Microvascular Blood Flow in Sickle Cell Anemia Is Triggered by Autonomic Signals and Not Directly by Hypoxia: A New Hypothesis for Sickle Crisis.. Blood, 2009, 114, 1523-1523.	1.4	1
191	Quantitative CT Accurately Predicts Liver Iron Concentration in Transfusional Siderosis.. Blood, 2009, 114, 4053-4053.	1.4	0
192	Transfusion Therapy Decreases Oxygen Transport to Low-Flow Vascular Beds in Sickle Cell Disease.. Blood, 2009, 114, 1518-1518.	1.4	0
193	Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis. Journal of Magnetic Resonance Imaging, 2008, 28, 698-704.	3.4	73
194	Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology, 2008, 83, 263-270.	4.1	41
195	Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. British Journal of Haematology, 2008, 141, 891-894.	2.5	67
196	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone, 2008, 43, 162-168.	2.9	64
197	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	3.5	67
198	Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141.	1.4	56

#	Article	IF	Citations
199	Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica, 2008, 93, 917-920.	3.5	93
200	Abnormal autonomic cardiac response to transient hypoxia in sickle cell anemia. Physiological Measurement, 2008, 29, 655-668.	2.1	32
201	Abnormal cardiac autonomic control in sickle cell disease following transient hypoxia. , 2008, 2008, 1996-9.		9
202	Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. Haematologica, 2008, 93, 311-312.	3.5	17
203	Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 2008, 112, 2973-2978.	1.4	191
204	Sickle Cell Patients Have Exagerated Autonomic Response to Transient Hypoxia. Blood, 2008, 112, 124-124.	1.4	1
205	Pancreatic Iron and Pancreatic Function in Thalassemia. Blood, 2008, 112, 3876-3876.	1.4	3
206	Deferasirox (ExjadeÂ®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused Î²-Thalassemia Patients: An MRI T2* Study. Blood, 2008, 112, 3882-3882.	1.4	4
207	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with Î²-thalassemia. Clinical Therapeutics, 2007, 29, 909-917.	2.5	123
208	Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients. Pharmacoeconomics, 2007, 25, 329-342.	3.3	67
209	A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	2.5	255
210	Consequences and costs of noncompliance with iron chelation therapy in patients with transfusionâ€dependent thalassemia: a literature review. Transfusion, 2007, 47, 1919-1929.	1.6	151
211	ExjadeÂ® Reduces Cardiac Iron Burden in Chronically Transfused Î²-Thalassemia Patients: An MRI T2* Study.. Blood, 2007, 110, 2781-2781.	1.4	4
212	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5
213	Economic Burden of Sickle Cell Disease among Children and Adults.. Blood, 2007, 110, 958-958.	1.4	3
214	Vitamin D Deficiency Is Associated with Cardiac Iron Loading in Thalassemia Major.. Blood, 2007, 110, 574-574.	1.4	0
215	Leukocyte Apoptosis and Mitochondrial Dysfunction in Î²-Thalassemia Patients Treated with Deferasirox or Deferoxamine.. Blood, 2007, 110, 2773-2773.	1.4	0
216	Onset of Cardiac Iron Loading in Pediatric Patients.. Blood, 2007, 110, 2765-2765.	1.4	0

#	Article	IF	Citations
217	Electrocardiographic Screening for Cardiac Iron in Thalassemia Major.. Blood, 2007, 110, 2766-2766.	1.4	0
218	Secretory Phospholipase A2Levels in Patients with Sickle Cell Disease and Acute Chest Syndrome. Hemoglobin, 2006, 30, 165-170.	0.8	27
219	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	1.4	636
220	Spectral imaging microscopy web sites and data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2006, 69A, 863-871.	1.5	33
221	MRI detects myocardial iron in the human heart. Magnetic Resonance in Medicine, 2006, 56, 681-686.	3.0	509
222	Improved R2* measurements in myocardial iron overload. Journal of Magnetic Resonance Imaging, 2006, 23, 9-16.	3.4	141
223	Influence of Iron Chelation Therapy on R1 and R2 Calibration Curves in Gerbil Liver and Heart.. Blood, 2006, 108, 1775-1775.	1.4	0
224	Twice-Daily Deferasirox Improves Cardiac Iron Chelation in the Gerbil Model of Iron Cardiomyopathy.. Blood, 2006, 108, 1777-1777.	1.4	0
225	Single and Combination Drug Therapy for Fetal Hemoglobin Augmentation in Hemoglobin E-Î²0-Thalassemia: Considerations for Treatment. Annals of the New York Academy of Sciences, 2005, 1054, 250-256.	3.8	14
226	Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 386-395.	3.8	119
227	Fetal haemoglobin augmentation in E/beta0 thalassaemia: clinical and haematological outcome. British Journal of Haematology, 2005, 131, 378-388.	2.5	59
228	Mechanisms of tissue-iron relaxivity: Nuclear magnetic resonance studies of human liver biopsy specimens. Magnetic Resonance in Medicine, 2005, 54, 1185-1193.	3.0	87
229	Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy. Circulation, 2005, 112, 535-543.	1.6	212
230	COBALAMIN C DISEASE PRESENTING WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. Pediatric Hematology and Oncology, 2005, 22, 717-721.	0.8	25
231	MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 2005, 106, 1460-1465.	1.4	894
232	Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.. Blood, 2005, 106, 3134-3134.	1.4	1
233	Once-Daily Oral Deferasirox (ExjadeÂ®, ICL670) Versus Infusional Deferoxamine as Iron Chelation Therapy in Patients with Sickle-Cell Disease Receiving Frequent Transfusions: A Cost-Effectiveness Analysis.. Blood, 2005, 106, 5584-5584.	1.4	2
234	Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (ExjadeÂ®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.. Blood, 2005, 106, 1341-1341.	1.4	6

#	Article	IF	Citations
235	Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.. Blood, 2005, 106, 5583-5583.	1.4	0
236	Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Nonâ€ionic Surfactant in the Management of Acute Chest Syndrome. Hemoglobin, 2004, 28, 85-102.	0.8	49
237	Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood, 2004, 103, 1934-1936.	1.4	315
238	Dose Response of Deferoxamine, Deferiprone, and ICL670 Chelation Therapy in a Gerbil Model of Iron Overload.. Blood, 2004, 104, 3621-3621.	1.4	5
239	Evaluation of Chronic Transfusion (Tx) Practices in Children with Sickle Cell Disease (SCD): A Survey of STOP II Investigators.. Blood, 2004, 104, 3732-3732.	1.4	4
240	Cardiac MRI (T2,T2*) Predicts Cardiac Iron in the Gerbil Model of Iron Cardiomyopathy.. Blood, 2004, 104, 376-376.	1.4	2
241	Acute Chest Syndrome Is Strongly Associated Parvo Virus B19 Seroconversion in Patients with Hemoglobin SC Disease.. Blood, 2004, 104, 1664-1664.	1.4	0
242	Classification of simple stimuli based on detected nerve activity. IEEE Engineering in Medicine and Biology Magazine, 2003, 22, 64-76.	0.8	5
243	Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood, 2003, 102, 1506-1514.	1.4	141
244	A practical approach to neutrophil disorders. Pediatric Clinics of North America, 2002, 49, 929-971.	1.8	21
245	A case of neutropenia with transient absence of neutrophil chemotaxis. Annals of Allergy, Asthma and Immunology, 2002, 88, 445-450.	1.0	1
246	Control and monitoring of a parallel processed neural network via the World Wide Web. Neurocomputing, 2000, 32-33, 1021-1026.	5.9	0
247	Function of the cytoskeleton in human neutrophils and methods for evaluation. Journal of Immunological Methods, 1999, 232, 89-109.	1.4	26
248	Periodic formation of nascent lamellae is driven by changes in the stable F-actin pool of polymorphonuclear neutrophils after stimulation with chemotactic peptide and cross-linking of CD18 or CD61. Cytoskeleton, 1999, 44, 234-247.	4.4	2
249	An In Vitro Model of Human Red Blood Cell Production From Hematopoietic Progenitor Cells. Blood, 1998, 91, 2664-2671.	1.4	82
250	Behavioral aspects of neutrophil motility. Current Opinion in Hematology, 1996, 3, 41-47.	2.5	6
251	Increased neutrophil respiratory burst in bcr-null mutants. Cell, 1995, 80, 719-728.	28.9	174
252	Shape oscillations: a fundamental response of human neutrophils stimulated by chemotactic peptides?. FEBS Letters, 1995, 359, 229-232.	2.8	21

#	Article	IF	Citations
253	ADP-ribosylation of Rho enhances actin polymerization-coupled shape oscillations in human neutrophils. FEBS Letters, 1995, 372, 161-164.	2.8	21
254	Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. Journal of Cellular Physiology, 1994, 160, 154-162.	4.1	136
255	Comparison of buffy coat preparation to direct method for the evaluation and interpretation of bone marrow aspirates. American Journal of Hematology, 1993, 43, 107-109.	4.1	1
256	Development of a shape vector that identifies critical forms assumed by human polymorphonuclear neutrophils during chemotaxis. Cytometry, 1993, 14, 832-839.	1.8	4
257	Analysis of multi-parameter video measurements of human neutrophil movement and its relation to cell shape and cytosolic calcium. Computer Methods and Programs in Biomedicine, 1993, 39, 195-201.	4.7	7
258	Brief Report: Treatment of Chronic Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib with Colony-Stimulating Factors. New England Journal of Medicine, 1992, 326, 1666-1669.	27.0	117
259	An integrated system for quantitation of chemotaxis using a 48-well millipore filter assay. Computer Methods and Programs in Biomedicine, 1992, 38, 177-192.	4.7	2
260	Thrombocytosis and Hyposplenism in an Infant with Fetal Hydantoin Syndrome. Journal of Pediatric Hematology/Oncology, 1992, 14, 62-65.	0.6	5
261	Qualitative Functional Deficiency of Affinity-Purified Lactoferrin from Neutrophils of Patients with Chronic Myelogenous Leukemia, and Lactoferrin/H-Ferritin-Cell Interactions in a Patient with Lactoferrin-Deficiency with Normal Numbers of Circulating Leukocytes. Pathobiology, 1991, 59, 26-35.	3.8	3
262	Inhibition of production of LTB4 and chemotactic agent from rat alveolar macrophages treated with t-butyl hydroperoxide is independent of ATP depletion. Lipids and Lipid Metabolism, 1990, 1045, 9-16.	2.6	7
263	Effectiveness of two methods of parenteral nutrition support in improving muscle mass of children with neuroblastoma or Wilms' Tumor. A randomized study. Cancer, 1989, 64, 116-125.	4.1	17
264	Integration of nutrition support into oncologic treatment protocols for high and low nutritional risk children with Wilms' tumor. A prospective randomized study. Cancer, 1989, 64, 491-509.	4.1	33
265	Role of Selenium-Dependent Glutathione Peroxidase in Antioxidant Defenses in Rat Alveolar Macrophages. Experimental Lung Research, 1988, 14, 921-936.	1.2	23
266	Treatment of Antibody-Mediated Pure Red-Cell Aplasia with High-Dose Intravenous Gamma Globulin. New England Journal of Medicine, 1987, 317, 1004-1008.	27.0	99
267	Nutritional Support of Children with Neoplastic Diseases. Surgical Clinics of North America, 1986, 66, 1197-1212.	1.5	33
268	Planning and implementing a nutrition program for children with cancer. Topics in Clinical Nutrition, 1986, 1, 71-86.	0.4	3
269	The value of nutrition support in children with cancer. Cancer, 1986, 58, 1904-1910.	4.1	37
270	Angiomatoid Malignant Fibrous Histiocytoma with Extensive Lymphadenopathy Simulating Castleman's Disease. Pediatric Pathology, 1986, 6, 233-247.	0.5	17

#	Article	IF	Citations
271	A microcomputer-based program for video analysis of chemotaxis under agarose. Computer Methods and Programs in Biomedicine, 1985, 21, 195-202.	4.7	14
272	Magnetic resonance imaging of lymphomas in children. Pediatric Radiology, 1985, 15, 179-183.	2.0	21
273	Short- and long-term effectiveness of enteral and parenteral nutrition in reversing or preventing protein-energy malnutrition in advanced neuroblastoma a prospective randomized study. Cancer, 1985, 56, 2881-2897.	4.1	53
274	Effect of nutrition staging on treatment delays and outcome in stage IV neuroblastoma. Cancer, 1983, 52, 587-598.	4.1	82
275	Lactoferrin Deficiency Associated with Altered Granulocyte Function. New England Journal of Medicine, 1982, 307, 404-410.	27.0	170
276	Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer, 1980, 46, 1548-1554.	4.1	119